Here is the content you requested:
Updated evidence-based recommendations for cervical cancer screening in… Following other countries in Europe and elsewhere (Lew et al., 2017; CADTH, 2019; American Cancer Society, 2020; Maver and Poljak, 2020), France has also recommended the use of the HPV test as the primary cervical cancer screening method, in July 2019. A year later, in July 2020, these recommendations were officially integrated into the national population-based cervical cancer screening …Source
(Cervical cancer screening pathways in France in 2015-2021, a … Screening pathways as 2015 for women screened in 2021 2a Women undergoing opportunistic screening in 2021 in France From center to edge: 1st circle: interval between screening in 2021 and last …
France] in France, recent advances in cervical cancer screening include an organized cervical cancer-screening program and the introduction of HPV testing as a first-line test for women aged 30-65 years. The HPV test, performed on a cervical smear taken by a health professional, could also be performed on a vaginal self-sample in certain …e CCU reduction strategies are therefore not yet achieved, whether they are those set nationally, at European level or by WHO.Improvements remain necesary. Study authors note that if the screening invitation strategy has been followed by an increase in the screening rate and affected all the age groups concerned, and in particular the highest, spontaneous screening to be remote (1). Vital awareness efforts remain necessary, notably in certain territories where they must be adapted due to various obstacles: socio-economic inequalities, restricted access to information and health professionals, variable acceptance of health actions public, brakes of cultural origin.
References:
- C. audiger, J.Plaine J et al. Effect of the implementation of the organized program of uterus cancer screening on coverage rates in France: comparative analysis of periods 2015-2017 and 2020-2022. Bull epidemiol Hebd. 2025; (3-4): 33-40.
- C. Audiger, L. Fonteneau et al. Prevention of cervical cancer in france: inventory of vaccination and screening and analysis of territorial disparities, 2020-2023. Bull epidemiol Hebd. 2025; (3-4): 26-32.
Expert Interview: FranceS Adoption of HPV Testing for Cervical Cancer Screening
Table of Contents
Recent updates in France’s healthcare policies have brought notable changes to cervical cancer screening protocols. The adoption of HPV testing as the primary screening method is one such advancement, following the recommendations of several international organizations. This interview features Dr. Isabelle Lefevre, a renowned specialist in cervical cancer screening, discussing these changes and their implications.
Recommending HPV Testing as the Primary Screening Method
Long/styles=”font-weight: bold;”>Editor (LT): When did France begin recommending HPV testing as the primary method for cervical cancer screening?
Dr. Lefevre: France first recommended HPV testing as the primary cervical cancer screening method in July 2019. These recommendations were officially integrated into our national population-based screening program a year later, in July 2020. This decision was backed by evidence from various international studies and aligns with recommendations from organizations like the American Cancer society.
Adapting Screenings to Include Self-Sampling
LT: Can you tell us more about the implementation of HPV testing and its effect on cervical cancer screening pathways?
Dr. Lefevre: the HPV test can be performed on a cervical smear taken by a healthcare professional. Though, there is also an option for self-sampling from a vaginal sample. This inclusion in our screening pathways is important because it can potentially increase compliance and reduce socio-economic barriers by offering a less invasive method, making screening more accessible.
Challenges in Cervical Cancer Screening
LT: What are some of the challenges faced in cervical cancer screening programs in France?
Dr. Lefevre: While the organized screening program and HPV testing have seen improvements, there are still challenges, especially in ensuring consistent screening rates across all age groups and socio-economic demographics. We’ve noted that socio-economic inequalities, restricted access to healthcare details and professionals, and cultural factors also play a role in determining screening outcomes.
Improving Awareness and Access
LT: How do you think awareness efforts can be enhanced to increase screening rates in challenged regions?
Dr. Lefevre: Crucial awareness efforts are necessary, especially in territories with socio-economic inequalities and limited access to healthcare. Adapting these efforts based on local needs, providing culturally suitable information, and ensuring access to healthcare professionals are key steps.Tailored educational campaigns targeting these communities can also improve acceptance of and participation in screening programs.
Looking Ahead
LT: What are the future goals for cervical cancer screening in France?
Dr. Lefevre: Our future goals include continuing the implementation of HPV testing as the primary screening method and addressing the remaining disparities in screening coverage. Ongoing research, improved access to screening, and enhanced education are essential for achieving these objectives and reducing cervical cancer incidence effectively.
